New cancer treatment could reduce side effects

Image
IANS New York
Last Updated : Sep 11 2015 | 4:28 PM IST

Researchers have discovered a new strategy for attacking cancer cells that has the potential to reduce side effects of the treatment, fundamentally changing the way doctors treat and prevent the deadly disease.

"We think we have a way not only to more specifically target cancer cells, but a way that could become a frontline treatment for women who have cancers of many types and want to preserve fertility," said one of the researchers John Herr from the University of Virginia School of Medicine in the US.

In their study of germ cells - the reproductive cells that make up sperm and eggs - the researchers found a link between developing egg cells and tumours.

The researchers found that a protein called SAS1B that is typically found only on the surface of developing and mature egg cells is also expressed in breast, melanoma, uterine, renal, ovarian, head and neck, and pancreatic cancers.

"The research reveals a previously little known fundamental aspect of cancer - that many types of cancer, when they dysregulate or go awry, revert back and take on features of the egg, the original cell from which all the tissues in the body derive," Herr said.

The researchers found a way to exploit this fundamental insight by developing a method for delivering medication using the SAS1B protein as a target.

"You add a SAS1B-targeted antibody with a drug on it, and within 15 minutes of contacting the cancer cells, the antibody binds at the cell surface and the antibody-SAS1B complexes begin the internalisation process," Herr said.

After about an hour, the antibody-SAS1B complexes reach compartments inside the cell and release their toxic drug payload, triggering changes leading to cell death within a few days, the study said.

This kind of targeted drug delivery could mean a dramatic reduction in the difficult side effects of traditional cancer treatment such as hair loss, nausea, anemia and neuropathy.

The findings were published in the scientific journal Oncotarget.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 11 2015 | 4:18 PM IST

Next Story